Skip to main content
. Author manuscript; available in PMC: 2015 Sep 28.
Published in final edited form as: J Control Release. 2014 Jun 28;190:314–330. doi: 10.1016/j.jconrel.2014.06.028

Table 3.

Therapeutic ELP depots

Application ELP sequence Functionalization Ref
Depots for cancer (VPGVG)120 Tyrosine residue for conjugation of 125I or 131I radionuclides [97]
(VPGVG)60, 120, or 240 1, 4, or 7 tyrosine residues for conjugation of 125I or 131I radionuclides [98]
(VPGXG)160 or 168 X=A14V1C1 or VaCb where a:b=15:1, 9:1, or 5:1 Cysteine residues for disulfide cross-linking and tyrosine residues for conjugation of 125I radionuclide [99]
Depots for joint degeneration (VPGVG)47 kDa 14C labeling for visualization of prolonged residence in rat knee joint [100]
(VPGXG)90 X=V5G3A2 and (VPGVG)30 IL-1Ra for anti-inflammatory treatment of osteoarthritis [101]
[(VPGKG)-(VPGVG)16]6 Lysine residues for THPP cross-linking and physical encapsulation of vancomycin and cefazolin antibiotics [102]
Depots for neuroinflammation (VPGVG)120 Tritium radiolabeling for visualization of prolonged residence in perineural space [103]
(VPGVG)60 sTNFRII for anti-inflammatory treatment of dorsal root ganglion [104, 105]
(VPGXG)60, 80, or 160 X=V1I3E1 Glutamate residues for conjugation of curcumin with degradable carbamate linker [106]
Depots for diabetes (VPGVG)120 GLP-1 fusion for release of macromolecular peptide drug carrier [107]
(VPGVG)240 (GLP-1)6 fusion via protease cleavable arginine linkers for release of free peptide drug [108]